Presentation is loading. Please wait.

Presentation is loading. Please wait.

Dr: Wael H.Mansy, MD Assistant Professor College of Pharmacy King Saud University Diabetes Mellitus.

Similar presentations


Presentation on theme: "Dr: Wael H.Mansy, MD Assistant Professor College of Pharmacy King Saud University Diabetes Mellitus."— Presentation transcript:

1 Dr: Wael H.Mansy, MD Assistant Professor College of Pharmacy King Saud University Diabetes Mellitus

2 List the effects of insulin and glucagon in the body. List the factors that put an individual at risk for developing diabetes. Discuss the possible etiology of type I and type II diabetes. Define the three “ploys.” Why do they occur? What are the manifestations of diabetic ketoacidosis? Why does it occur? What is hyperosmolar -hyperglycemic syndrome? Why does it occur? Discuss pharmacologic and nonpharmacologic treatment for diabetes. Discuss possible mechanisms of tissue injury in diabetes mellitus. List the major effects of chronic diabetes mellitus. Why does each occur? Define gestational diabetes Diabetes Mellitus Study Objectives

3 Diabetes Mellitus Group of metabolic disorders characterized by hyperglycemia resulting from either or both: insufficient insulin secretion resistance to the action of insulin Abnormalities in carbohydrate, fat, protein metabolism

4 Effects of Insulin on Various Tissues 4 Adipose Tissue Increased glucose entry Increased fatty acid synthesis Increased glycerol phosphate synthesis Activation of lipoprotein lipase Inhibition of hormone-sensitive lipase Increased K + uptake Muscle Increased glucose entry Increased glycogen synthesis Increased amino acid uptake Increased protein synthesis in ribosomes Decreased release of gluconeogenic amino acids Increased ketone uptake Increased K + uptake Liver Decreased ketogenesis Increased protein synthesis Increased lipid synthesis Decreased glucose output due to decreased gluconeogenesis, increased glycogen synthesis, and increased glycolysis General Increased cell growth

5 5 Insulin stimulates hepatic glucose storage as glycogen; in adipose tissue as triglycerides; and amino acid storage in muscle as protein; it also promotes utilization of glucose in muscle for energy. These pathways, which also are enhanced by feeding, are indicated by the solid blue arrows. Insulin inhibits the breakdown of triglycerides, glycogen, & protein and conversion of amino acids to glucose (gluconeogenesis), as indicated by the white arrows. These pathways are increased during fasting and in diabetic states. Conversion of amino acids to glucose & glucose to fatty acids occurs primarily in the liver.

6 6

7 Diabetes Classification Majority of diabetics classified in 2 categories: type 1: absolute deficiency of insulin type 2: presence of insulin resistance with reduced insulin secretion Gestational diabetes triggered by stress of pregnancy Other specific types: infections, drugs, endocrinopathies, pancreatic destruction, genetic defects 7 7

8

9 Type 1 DM Autoimmune destruction of pancreatic β-cells ~90% of patients have markers of immune β-cell destruction at diagnosis children & adolescents often have rapid β-cell destruction & present with ketoacidosis may occur at any age Known as latent autoimmune diabetes in adults (LADA) slowly progressive sufficient insulin secretion to prevent ketoacidosis for many years 9 9

10  Latent Autoimmune Diabetes in Adults (LADA) is a form of autoimmune (type 1 diabetes) which is diagnosed in individuals who are older than the usual age of onset of type 1 diabetes.autoimmunetype 1 diabetes  Alternate terms that have been used for "LADA" include Late-onset Autoimmune Diabetes of Adulthood, "Slow Onset Type 1" diabetes, and sometimes also "Type 1.5  Often, patients with LADA are mistakenly thought to have type 2 diabetes, based on their age at the time of diagnosis.type 2 diabetes LADA

11 LADA (cont.) (Islet Cell Antibodies) (Glutamic Acid Decarboxylase Autoantibodies)

12 Type 1 DM Pathogenesis 1. Preclinical period immune markers present β-cell destruction 2. Hyperglycemia 80 to 90% of β-cells destroyed 3. Transient remission honeymoon phase 4. Established disease 12

13 Type 2 DM Insulin resistance, relative lack of insulin secretion Usually presents with cluster of abnormalities known as metabolic syndrome: abdominal obesity hypertension dyslipidemia elevated PAI-1 (plasminogen activator inhibitor-1) levels Increased macrovascular complication risk 13

14 14 NCEP ATP III: Components of the Metabolic Syndrome (> 3 for diagnosis) Risk FactorDefining Level Abdominal obesity a Men (waist circumference) b > 102 cm (> 40 in.) Women> 88 cm (> 35 in.) Triglycerides> 1.7 mmol/L (> 150 mg/dL) HDL cholesterol Men< 1.0 mmol/L (< 40 mg/dL) Women< 1.3 mmol/L (< 50 mg/dL) Blood Pressure≥ 130/≥ 85 mmHg Fasting glucose> 6.1 mmol/L ( > 110 mg/dL) NCEP-ATP: National Cholesterol Education Program Adult Treatment Panel

15 Screening Type 1 not recommended low prevalence, acute symptoms Type 2 fasting plasma glucose (FPG) recommended alternative: oral glucose tolerance test (OGTT) more costly, less convenient, less reproducible HbA1c (HbA1c reflects glucose levels for the previous 2 to 3 months) not recommended no gold standard assay useful in monitoring glycemic control after diagnosis 15

16 Glucose Tolerance Test 16 Blood glucose curves of a normal and a diabetic person after oral administration of 1 g of glucose/kg body weight. Note the initial raised concentration in the fasting diabetic. A criterion of normality is the return of the curve to the initial value within 2 hours.

17 17 Type 2 DM Screening a BMI > 85 th percentile for age & sex, > 85 th percentile weight for height, or > 120% of ideal weight for height b Family history of DM2 in 1 st or 2 nd degree relative; high risk ethnic group; signs of insulin resistance; maternal history of gestational diabetes during child’s gestation c BMI ≥ 25kg/m 2 ADA Type 2 Diabetes Screening Recommendations Children & AdolescentsEvery 3 years at age 10 or onset of puberty if overweight a with two additional risk factors b AdultsEvery 3 years in adults ≥ 45 years of age or earlier if overweight c & additional risk factors present American Diabetes Association. Standards of medical care in diabetes Diabetes Care 2009;32:S13-S61.

18 BMI ≥ 25 Physical inactivity 1 st degree relative with DM High risk ethnic group ( Latino, African American, Native American, Asian American, Pacific Islander) IFG, IGT HTN: ≥ 140/90 mmHg or on therapy for HTN CV disease HDL < 35 mg/dL Triglycerides > 250 mg/dL Delivery of > 9 lb baby History of GDM Insulin resistance Polycystic ovary syndrome 18 Type 2 DM Risk Factors American Diabetes Association. Standards of medical care in diabetes Diabetes Care 2009;32:S13-S61.

19 Screening for Gestational DM Risk assessment at 1 st prenatal visit Screen high risk women as soon as possible family history of DM history of GDM marked obesity presence of glycosuria diagnosis of PCOS If initial screening negative, retest high risk women at 24 to 28 weeks gestation 19 American Diabetes Association. Standards of medical care in diabetes Diabetes Care 2009;32:S13-S61.

20  Any degree of glucose intolerance with onset or first recognition during pregnancy, most commonly seen during the third trimester of pregnancy ( in about 1 to 6% of pregnancies).  More common among obese women and women with a family history of diabetes.  Resolves itself in most patients after birth but in certain percentage (50 to 60%) type 2 diabetes will develop within 10 yrs of initial diagnosis.  May be associated with an increased risk of fetal abnormalities.  Currently recommended that all pregnant women be screened for the presence of gestational diabetes. Diabetes Mellitus Gestational diabetes mellitus

21 21 Diagnosis Normal FPG < 100 mg/dL 2 hr postload plasma glucose < 140 mg/dL Impaired fasting glucose (IFG) FBG = 100 to 125 mg/dL Impaired glucose tolerance (IGT) 2 hr postload plasma glucose = 140 to 199 mg/dL Diabetes mellitus FPG ≥ 126 mg/dL 2 hr postload plasma glucose ≥ 200 mg/dL

22 22 Diagnosis In absence of unequivocal hyperglycemia: confirm on different day a Fasting: no caloric intake for at least 8 hours b Classic symptoms: polyuria, polydipsia, unexplained weight loss c Causal: any time of day without regard to last meal d Oral glucose tolerance test: equivalent to 75-g anhydrous glucose in H2O; not recommended for routine clinical use DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM: Pharmacotherapy: A Pathophysiologic Approach, 7th Edition: ADA Criteria for DM Diagnosis 1Fasting a plasma glucose (FBG) ≥ 126 mg/dL 2Symptoms of diabetes b & casual c plasma glucose ≥ 200 mg/dL 32-hour plasma glucose ≥ 200 mg/dL during OGTT d

23 23

24 Characteristic Type 1 DM Type 2 DM Age< 30 years b > 30 years b OnsetAbruptGradual Body habitusLeanObese or history of obesity Insulin resistanceAbsentPresent AutoantibodiesOften presentRarely present SymptomsSymptomatic c Often asymptomatic Ketones at diagnosisPresentAbsent d Need for insulin therapyImmediateYears after diagnosis Acute complicationsDiabetic ketoacidosis Hyperosmolar hyperglycemic state Microvascular complications at diagnosis NoCommon Macrovascular complications at or before diagnosis RareCommon 24 Clinical Presentation of Diabetes a a Clinical presentation can vary widely. b Age of onset for type 1 DM is generally < 20 years of age but can present at any age. The prevalence of type 2 DM in children, adolescents, and young adults is increasing. This is especially true in ethnic and minority children. c Type 1 can present acutely with symptoms of polyuria, nocturia, polydipisia, polyphagia, weight loss. d Type 2 children and adolescents are more likely to present with ketones but after the acute phase can treated with oral agents. Prolonged fasting can also produce ketones in individuals.

25 Manifestations: Symptoms of diabetes appear when the levels of glucose are either very high or very low. Many persons with diabetes and all those with pre-diabetes do not have symptoms. Children may also feel very tired all the time. Diabetes Mellitus

26 Manifestations: Weight loss. The three “ploys” : Polydepsia (increased thirst), Polyphagia (increased appetite), Polyuria (increased urine output). Weakness and fatigue due to poor energy utilization and skeletal muscle catabolism. Diabetes Mellitus

27 Why do the three “polys” occur? Polyuria :Excess blood glucose filtered by the kidneys cannot be reabsorbed and is eliminated at the expense of water. Polydepsia : Excessive thirst caused by the osmotic diuresis of glucose and subsequent tissue dehydration. The thirst response is mediated by the hypothalamus. Polyphagia: Poor utilization of carbohydrates (due to the lack of insulin) results in depletion of stored fats, proteins and carbohydrates. Diabetes Mellitus

28 Diabetic ketoacidosis Accumulation of acidic ketone bodies in the blood due to a lack of insulin stimulated fatty acid utilization. Much more common in type I than type 2 - INSULIN Fatty Acids INSULIN+ Energy Ketone Bodies (β-hydroxybutyrate) (acetoacetate) (acetone) Diabetes Mellitus Manifestations:

29 Manifestations of Diabetic Ketoacidosis  Decreased blood pH levels.  Ketonuria — Appearance of excess ketones in the urine.  Lethargy.  Nausea and vomiting  Severe dehydration.  Markedly increased respiratory rate as an attempt to correct decreased blood pH.  Acetone breath — Acetone is a volatile ketone body that is eliminated via the lungs; may be noticeable in the exhaled air during diabetic ketoacidosis.  Coma and possible death. Diabetes Mellitus Manifestations:

30 Hyperglycemic Hyperosmolar Syndrome  A syndrome of type I diabetes mellitus that can result from acute insulin deficiency.  It may often accompany diabetic ketoacidosis. The manifestations include:  Severe dehydration  Extreme thirst  Serum osmolarity over 300 mOsm due to excessive glucose in the blood  Osmotic diuresis of glucose  Depressed neurologic function  Possible shock, coma and death Diabetes Mellitus Manifestations:

31 MacrovascularMicrovascular Stroke Heart disease and hypertension 2-4 X increased risk Foot problems Diabetic eye disease (retinopathy and cataracts) Renal disease Peripheral Neuropathy Peripheral vascular disease Diabetes: Complications Meltzer et al. CMAJ 1998;20(Suppl 8):S1-S29. Complications Erectile Dysfunction

32 Chronic diabetes mellitus is associated with significant increases in the incidence of coronary artery disease, cerebrovascular disease and peripheral vascular disease. May be due to a number of factors including elevated serum lipid levels, vascular injury, and enhanced atherogenesis (formation of atherosclerotic lesions). Coronary artery disease and stroke are significant sources of mortality and morbidity in patients with diabetes. Peripheral vascular disease can lead to gangrene and amputations (particularly of the toes and feet) in people suffering from diabetes. Diabetes Mellitus Complication: 1.Vascular Diseases

33 Abnormality of nerve conduction and function. Often affects peripheral nerves. Can involve sensory or motor neurons. May manifest as numbness, pain or sensory/motor impairment. Often progressive and irreversible. Although the exact cause is unknown, the neuropathy may be related to ischemia or altered nerve cell metabolism. 2.Diabetic neuropathy Diabetes Mellitus Complication:

34  The most serious consequence of long-term diabetes in terms of the eye is retinal damage.  The retina is a highly metabolic tissue that is especially vulnerable to the effects of chronic hypoxia and diabetes.  Hemorrhage of eye capillaries and chronic inflammation is common and can lead to increases in intraocular pressure that scar the retina and impair vision. This phenomenon is usually progressive and can lead to blindness.  Diabetes is also associated with an increased incidence of glaucoma and cataract formation. 3.Diabetic Retinopathy Diabetes Mellitus Complication: Pathogenesis of DR:

35 Diabetes Mellitus Complication: Diabetic Retinopathy

36 It is a progressive kidney disease caused by angiopathy of capillaries in the kidney glomeruli.  The glomerular injury is characterized by thickening of the glomerular basement membrane and glomerulosclerosis.  Although the exact etiology is unclear, trapping of glycosylated proteins in the glomeruli appears to be a key contributing factor.  The appearance of protein (albumin) in the urine is an early indicator of altered glomerular permeability (Microalbuminuria).  Renal function may continue to deteriorate as glomerular filtration decreases.  Signs and symptoms of renal failure will appear as renal function continues to decline. Diabetes Mellitus Complication: 4.Diabetic Nephropathy

37  As a result of peripheral vascular disease, injuries in patients with diabetes do not heal properly. Poor blood flow limits the delivery of leukocytes and oxygen to the injured area while impairing removal of debris and infectious organisms.  The high glucose levels serve as a nutrient to support the growth of microorganisms.  Patients with diabetes might also be more susceptible to physical injuries as a result of impaired vision and sensory perception. Diabetes Mellitus Complication: 5. Impaired healing and increased infections

38 Erectile dysfunction Erectile dysfunction (ED, "male impotence") is sexual dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual performance. Since penile erection is neurovascular process, diabetic patients usually suffer from vascular complications that affect penile blood flow as well as neuropathies that disturb the nervous control of penile erection.

39  Loss of protective sensation.  Starts distally and migrates proximally in “stocking” distribution.  Mostly affects forefoot ulceration.  It results from repeated improper shoe ware, deformity or injury by glass or any other objects. Diabetes Mellitus Complication: 6. Diabetic Foot Pathogenesis:

40  Glycosylation of proteins : Attachment of glucose to proteins in the eye, blood vessel walls, and kidney membranes will change their structure and may lead to altered function and eventual damage of these tissues. Circulating glycosylated proteins may also be trapped in the glomeruli of the kidney, leading to inflammation and injury.  Formation of alcohol sugars e.g. sorbitol : Unlike glucose, alcohol sugars do not easily diffuse out of tissues. Because these alcohol sugars are osmotically active, they can lead to swelling and damage of tissues. The accumulation of other sugars such as galactose might also contribute to this phenomenon  Poor blood flow and oxygen delivery to tissues :Glycosylation of hemoglobin alters its affinity for oxygen while progressive vascular disease can reduce overall blood flow to tissues, leading to ischemic injury Possible Mechanisms of Tissue Injury in Chronic D M Diabetes Mellitus Complication:

41 NormalPre diabetesDiabetes Fasting Blood Glucose Test (FBG)* Less than 100 Between More than or equal to 126 Glucose Tolerance Test (GTT) ** Less than 140 Equal to or more than 140 but less than 200 More than or equal to 200 Diagnosis Criteria * FBG blood test is done after fasting 8 hours. ** GTT results are repeated after 2 hours. A person drinks a 75 mg glucose solution before test. 100 mg for Pregnant women. Diabetes Mellitus Diagnosis :

42 Diabetes Mellitus Treatment Optimal diabetes control is a careful balance of Diet, Exercise, and Insulin and/or oral medication GOAL: To maintain target blood glucose

43 Diabetes Self-management meal plan (always eating healthy) meal plan (always eating healthy) exercise moderately (eg. walking 30 minutes a day), Exercise may enhance glucose utilization and improve glucose control in patients with type II diabetes, thus reducing the risk of diabetic complications. exercise moderately (eg. walking 30 minutes a day), Exercise may enhance glucose utilization and improve glucose control in patients with type II diabetes, thus reducing the risk of diabetic complications. what a person with diabetes should do by her/himself to maintain control

44 insulin and/or oral medication food exercise The key to optimal diabetes control is a careful balance or juggling of food, exercise, and insulin and/or oral medication. As a general rule, insulin/oral medication and exercise/activity makes blood glucose levels go down. Treatment of diabetes mellitus Maintaining good blood glucose control is a constant juggling act, 24 hours a day, 7 days a week.

45 Less than one portion 2 to 3 portions 3 to 5 portions 6 to 11 portions 2 to 3 portions 2 to 4 portions

46 Insulin must be administered by injection because an oral form would be degraded in the gastrointestinal tract. Insulin is generally available in three preparations: Short-acting form : Peak action in 2–4 hours, duration 6–8 hours. Intermediate-acting form :Peak action in 6–12 hours, duration 12–24 hours. Long-acting form : Peak action 8–24 hours, duration 24–36 hours. Diabetes Mellitus Type I of diabetes mellitus Treatment:  Insulin replacement.

47 Oral therapy: prescribed after dietary control has been proven insufficient or if the client is highly symptomatic Classifications: Sulfonylureas Meglitnide analogs Biguanides Alpha-glucosidse inhibitors Thiazolidinedione antidiabetic agents Diabetes Mellitus Type II of diabetes mellitus

48 Frequent measurement of blood glucose levels Measurement of glycosylated hemoglobin (Hb A1c, hemoglobin that has glucose bound to it) that forms at a rate that increases with increasing blood glucose, which is a useful measure of blood glucose control in patients with diabetes. Monitoring of DM

49 BECAUSE… ☺Controlling Glucose Levels through Self Management  Every 1% drop of A1C significantly reduces the risk of eye, kidney, and nerve complications ☺Controlling Blood Pressure  Will reduce the risk of heart disease or stroke by 33% to 50%. ☺Controlling Lipids (fats)  Will reduce cardiovascular complications by 20% to 50%. ☺Careful foot care  Will reduce amputations rates by 45% to 85%. ☺Careful eye care  Will reduce the development of severe vision loss by 50% - 60%. ☺Careful kidney care  Will reduce the decline in kidney function by 30% - 70%. Why should we educate diabetics about diabetes?

50 THANK YOU


Download ppt "Dr: Wael H.Mansy, MD Assistant Professor College of Pharmacy King Saud University Diabetes Mellitus."

Similar presentations


Ads by Google